Aclaris Therapeutics, Inc. (0H8T.L)
USD 1.24
(-5.4%)
USD 1.24
(-5.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -87.98 Million USD | -39.37% |
| 2022 | -89.05 Million USD | -30.87% |
| 2021 | -89.94 Million USD | -36.58% |
| 2020 | -50.01 Million USD | 47.12% |
| 2019 | -111.95 Million USD | -8.59% |
| 2018 | -80.78 Million USD | -15.07% |
| 2017 | -71.42 Million USD | -60.75% |
| 2016 | -48.23 Million USD | -119.0% |
| 2015 | -20.28 Million USD | -138.09% |
| 2014 | -8.52 Million USD | -62.43% |
| 2013 | -5.24 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -13.38 Million USD | -924.42% |
| 2024 Q2 | -12.61 Million USD | 24.47% |
| 2023 Q3 | -22.31 Million USD | 31.44% |
| 2023 Q1 | -29.45 Million USD | -35.2% |
| 2023 FY | - USD | -34.74% |
| 2023 Q2 | -32.54 Million USD | -10.48% |
| 2023 Q4 | -20.39 Million USD | 8.62% |
| 2022 Q2 | -24.18 Million USD | -21.55% |
| 2022 FY | - USD | -30.87% |
| 2022 Q4 | -21.78 Million USD | -17.9% |
| 2022 Q3 | -18.48 Million USD | 23.59% |
| 2022 Q1 | -19.89 Million USD | 2.91% |
| 2021 Q2 | -12.95 Million USD | -9.8% |
| 2021 Q1 | -11.8 Million USD | 10.65% |
| 2021 Q3 | -19.2 Million USD | -48.19% |
| 2021 Q4 | -20.49 Million USD | -6.73% |
| 2021 FY | - USD | -36.58% |
| 2020 Q1 | -13.46 Million USD | 19.92% |
| 2020 FY | - USD | 47.12% |
| 2020 Q2 | -10.97 Million USD | 18.48% |
| 2020 Q3 | -9.54 Million USD | 13.0% |
| 2020 Q4 | -13.2 Million USD | -38.34% |
| 2019 Q3 | -22.72 Million USD | -2.26% |
| 2019 Q1 | -24.96 Million USD | -8.22% |
| 2019 FY | - USD | -8.59% |
| 2019 Q4 | -16.81 Million USD | 26.01% |
| 2019 Q2 | -22.22 Million USD | 11.01% |
| 2018 Q4 | -23.07 Million USD | -9.25% |
| 2018 FY | - USD | -15.07% |
| 2018 Q3 | -21.11 Million USD | -159.72% |
| 2018 Q1 | -29.86 Million USD | -20.62% |
| 2018 Q2 | -8.13 Million USD | 72.77% |
| 2017 Q1 | -12.88 Million USD | -17.78% |
| 2017 Q2 | -15.24 Million USD | -18.32% |
| 2017 Q3 | -18.64 Million USD | -22.31% |
| 2017 Q4 | -24.75 Million USD | -32.81% |
| 2017 FY | - USD | -60.75% |
| 2016 FY | - USD | -119.0% |
| 2016 Q4 | -10.93 Million USD | -1.45% |
| 2016 Q3 | -10.78 Million USD | 16.83% |
| 2016 Q2 | -12.96 Million USD | -33.18% |
| 2016 Q1 | -9.73 Million USD | -117.25% |
| 2015 Q1 | -2.62 Million USD | -1.04% |
| 2015 FY | - USD | -138.09% |
| 2015 Q3 | -10.6 Million USD | -312.12% |
| 2015 Q4 | -4.48 Million USD | 57.77% |
| 2015 Q2 | -2.57 Million USD | 1.98% |
| 2014 Q4 | -2.59 Million USD | 2.26% |
| 2014 Q1 | -1.63 Million USD | 0.0% |
| 2014 Q2 | -1.63 Million USD | 0.0% |
| 2014 Q3 | -2.65 Million USD | -62.98% |
| 2014 FY | - USD | -62.43% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | 65.237% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 74.531% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 4.446% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 66.923% |
| bluebird bio, Inc. | -167.16 Million USD | 47.365% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 25.215% |
| Imunon, Inc. | -20.78 Million USD | -323.366% |
| Editas Medicine, Inc. | -163.11 Million USD | 46.06% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 102.702% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 107.559% |
| Myriad Genetics, Inc. | -67.8 Million USD | -29.771% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 121.145% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 189.541% |
| Verastem, Inc. | -83.16 Million USD | -5.794% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.22% |
| Waters Corporation | 1.02 Billion USD | 108.607% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.815% |
| Biogen Inc. | 2.37 Billion USD | 103.702% |
| Nektar Therapeutics | -243.1 Million USD | 63.808% |
| Perrigo Company plc | 646.2 Million USD | 113.616% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1010.252% |
| Illumina, Inc. | -608 Million USD | 85.529% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -98.001% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 80.405% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 15.229% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -135.992% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 128.356% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -0.638% |
| Evolus, Inc. | -41.81 Million USD | -110.44% |
| Adicet Bio, Inc. | -136.53 Million USD | 35.559% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.89% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 41.386% |
| FibroGen, Inc. | -261.4 Million USD | 66.342% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 105.247% |
| OPKO Health, Inc. | -65.51 Million USD | -34.295% |
| Homology Medicines, Inc. | -47.75 Million USD | -84.239% |
| Geron Corporation | -174.78 Million USD | 49.66% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 61.431% |
| Exelixis, Inc. | 196.6 Million USD | 144.753% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 12.737% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -57.804% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 82.622% |
| Zoetis Inc. | 3.68 Billion USD | 102.388% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 60.894% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -73.98% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.911% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -143.847% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 61.747% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 79.967% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 181.224% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 119.468% |
| Blueprint Medicines Corporation | -474.61 Million USD | 81.462% |
| Insmed Incorporated | -654.73 Million USD | 86.562% |
| TG Therapeutics, Inc. | 26.1 Million USD | 437.107% |
| Incyte Corporation | 919.42 Million USD | 109.57% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 82.588% |